TY - JOUR T1 - Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease JF - Evidence Based Medicine JO - Evid Based Med SP - 115 LP - 115 DO - 10.1136/ebm.13.4.115 VL - 13 IS - 4 A2 - , Y1 - 2008/08/01 UR - http://ebm.bmj.com/content/13/4/115.abstract N2 - A K AkobengDr A K Akobeng, Booth Hall Children’s Hospital, Manchester, UK; tony.akobeng@cmmc.nhs.ukWhich interventions are effective for maintaining remission in Crohn’s disease?Included studies evaluated interventions for maintaining remission in Crohn’s disease. Outcome was maintenance of remission (or relapse).Medline (1966 to May 2007), Cochrane Library (Issue 2, 2007), and Cochrane Inflammatory Bowel Disease Group were searched for randomised controlled trials (RCTs) or systematic reviews or meta-analyses of RCTs. 8 interventions (azathioprine, 5-aminosalicylates, corticosteroids, budesonide, antimycobacterial agents, probiotics, omega-3 fatty acids, and enteral nutrition) were evaluated in systematic reviews, and 6 interventions (methotrexate, infliximab, adalimumab, natalizumab, certolizumab, and ciclosporin) were evaluated in RCTs. … ER -